QuantaBrain
QuantaBrain aims to revolutionize psychiatry with imaging-based biomarkers for precise diagnoses and personalized treatments, enhancing objectivity and patient-specific care.
- B2B
- saas
- subscription
- health
- medical devices
- artificial intelligence
- hardware
- big data
- deep tech
- machine learning
- computer vision
- connected device
- recognition technology
- iot internetofthings
| Date | Investors | Amount | Round |
|---|---|---|---|
| investor | €0.0 | round | |
* | N/A | Seed | |
| Total Funding | 000k | ||
| EUR | 2023 | 2024 |
|---|---|---|
| Revenues | 0000 | 0000 |
| % growth | - | 2845 % |
| EBITDA | 0000 | 0000 |
| Profit | 0000 | 0000 |
| % profit margin | (366 %) | (19 %) |
| EV | 0000 | 0000 |
| EV / revenue | 00.0x | 00.0x |
| EV / EBITDA | 00.0x | 00.0x |
| R&D budget | 0000 | 0000 |
Source: Company filings or news article
Related Content
QuantaBrain is a startup that has developed an artificial intelligence-based software for the diagnosis and characterization of mental, behavioral, and psychiatric disorders. The company's technology utilizes data from a brief, one-minute resting-state functional Magnetic Resonance Imaging (fMRI) to provide quantitative analysis of the brain.
This diagnostic approach aims to improve the process of identifying psychiatric and neurodevelopmental disorders by applying artificial intelligence to brain imaging data. The software is designed to not only diagnose these conditions but also to suggest personalized treatment plans. The company targets the healthcare sector, specifically psychiatric and neurodevelopmental diagnostics. The business model appears to be centered on providing this software as a clinical decision support tool.
Keywords: AI-based software, psychiatric disorders, neurodevelopmental disorders, fMRI, brain imaging, personalized treatments, quantitative analysis, mental health, diagnostic tool, medical software